Dr Reddy's files FY2026 Integrated Annual Report, BRSR, and AGM notice

Exceptional ItemEbitda Margin CompressionResults View source PDF

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.1%1-day move

₹1359.20

prior close

₹1351.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.3+0.1+0.2-0.8-1.1+0.9+0.4-0.4-0.6-8.3-13.2———

Up moveDown movePending

AI summary

Dr Reddy's has submitted its Integrated Annual Report, Business Responsibility and Sustainability Report (BRSR), and 42nd AGM notice for FY2025-26 to stock exchanges, sent electronically to members. Key highlights: revenue at Rs 3,35,933 mn (up 3.2%), EBITDA margin of 22.8% impacted by expected lenalidomide decline and one-off items including inventory adjustments, provisions, and impairment charges. India formulations grew 16%. Total 220 new product launches globally during the year.

Likely market impact

Routine annual filing provides transparency on FY2026 results. EBITDA margin compressed YoY due to one-off charges, though underlying business stays resilient with strong India growth.